UK Reviews Palantir NHS Contract
Analysis based on 20 articles · First reported Jun 02, 2026 · Last updated Jun 09, 2026
The ongoing review of Palantir' contract with the United Kingdom — National Health Service in the United Kingdom, coupled with parliamentary criticism and calls for termination, has negatively impacted Palantir' stock price. Broader market anxieties regarding potential United States — Federal Reserve interest rate hikes and AI stock valuations have further contributed to the selling pressure on Palantir. The uncertainty surrounding this significant public sector contract creates volatility for Palantir and raises questions about the United Kingdom's future reliance on foreign tech suppliers for critical infrastructure.
The United Kingdom government is conducting a full review of the United Kingdom — National Health Service's £330 million contract with U.S. data analytics firm Palantir. This review comes amid growing political pressure, including a parliamentary committee's recommendation to use a break clause in early 2027, citing concerns about over-reliance on U.S. tech firms, patient confidentiality, public trust, and a 'mismatch with UK values' due to Palantir' work with the U.S. military and co-founder Peter Thiel's political views. Technology Minister Liz Kendall announced the review, which will assess whether to extend the contract for up to seven years or terminate it. Palantir' British CEO Louis Mosley defended the contract, stating its cancellation would be 'irresponsible'. Separately, London Mayor Sadiq Khan previously blocked a police contract with Palantir over similar concerns. The broader market has also seen Palantir' stock decline due to general tech sector pullbacks and anxieties about potential United States — Federal Reserve interest rate hikes.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard